Jose A. Karam, M.D., FACS

Peer-Reviewed Articles

1. Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Pilié PG, Karki M, Seervai RNH, Vokshi BH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Davidson I, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell 37(5):720-734.e13, 2020. e-Pub 2020. PMID: 32359397.
2. Mendoza-Pérez J, Gu J, Herrera LA, Tannir NM, Zhang S, Matin S, Karam JA, Wood CG, Wu X. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma. Cancer 123(18):3617-3627, 2017. e-Pub 2017. PMID: 28543182.
3. Wood EL, Adibi M, Qiao W, Brandt J, Zhang M, Tamboli P, Matin SF, Wood CG, Karam JA. Local Tumor Bed Recurrence Following Partial Nephrectomy in Patients with Small Renal Masses. J Urol. e-Pub 2017. PMID: 28941919.
4. Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. e-Pub 2017. PMID: 28832979.
5. Wang Z, Kim TB, Peng B, Karam JA, Creighton CJ, Joon AY, Kawakami F, Trevisan P, Jonasch E, Chow CW, Rodriguez-Canales J, Tamboli P, Tannir NM, Wood CG, Monzon FA, Baggerly KA, Varella-Garcia M, Czerniak B, Wistuba II, Mills GB, Shaw K, Chen K, Sircar K. Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile and transcriptional landscape. Clin Cancer Res. e-Pub 2017. PMID: 28710314.
6. Chéry L, Borregales LD, Fellman B, Urbauer DL, Garg N, Parker N, Katz MHG, Wood CG, Karam JA. The Effects Of Neoadjuvant Axitinib On Anthropometric Parameters In Patients With Locally Advanced Non-Metastatic Renal Cell Carcinoma. Urology. e-Pub 2017. PMID: 28705573.
7. Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM, Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Miller VA, Agarwal N, Shuch B, Choueiri TK, Chung JH. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. Eur Urol. e-Pub 2017. PMID: 28592388.
8. Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA*, Tannir NM* (*co-senior authors). Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies Over Three Decades: Comparison Between the Cytokine (1987-2005) and the Targeted Therapy (2006-2015) Eras. J Urol. e-Pub 2017. PMID: 28411072.
9. Shu X, Hildebrandt MA, Gu J, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X. MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity. Br J Cancer 116(1):77-84, 2017. e-Pub 2016. PMID: 27907930.
10. Malouf GG, Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, Stephens PJ, Khayat D, Pal SK, Su X, Sircar K, Tamboli P, Jonasch E, Tannir NM, Wood CG, Karam JA. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. Eur Urol 70(2):348-57, 2016. e-Pub 2016. PMID: 26895810.
11. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favorable-risk prostate cancer undergoing active surveillance. BJU Int 118(1):68-76, 2016. e-Pub 2015. PMID: 26059275.
12. Abel EJ, Margulis V, Bauman TM, Karam JA, Christensen WP, Krabbe LM, Haddad A, Golla V, Wood CG. Risk Factors for Recurrence After Surgery in Non- metastatic RCC with Thrombus: a Contemporary Multicenter Analysis. BJU Int 117(6B):E87-94, 2016. e-Pub 2015. PMID: 26305276.
13. Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL. Intratumoral Heterogeneity: Role of Differentiation in a Potentially Lethal Phenotype of Testicular Cancer. Cancer 122(12):1836-43, 2016. e-Pub 2016. PMID: 27018785.
14. Huang H, Tamboli P, Karam JA, Vikram R, Zhang M. Secondary Malignancies Diagnosed Using Kidney Needle Core Biopsies: A Clinical And Pathological Study Of 75 Cases. Hum Pathol 52:55-60, 2016. e-Pub 2016. PMID: 26980018.
15. Malouf GG, Su X, Zhang J, Creighton CJ, Ho TH, Lu Y, Raynal NJ, Karam JA, Tamboli P, Allanick F, Mouawad R, Spano JP, Khayat D, Wood CG, Jelinek J, Tannir NM. DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. Clin Cancer Res. e-Pub 2016. PMID: 27256309.
16. Ho TH, Choueiri TK, Wang K, Karam JA, Chalmers Z, Frampton G, Elvin JA, Johnson A, Liu X, Lin Y, Joseph RW, Stanton ML, Miller VA, Stephens PJ, Ross JS, Ali SM, Pal SK. Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. Eur Urol Focus 2(2):204-209, 2016. e-Pub 2015. PMID: 28723536.
17. Kalra S, Atkinson BJ, Matrana MR, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int 117(5):761-5, 2016. e-Pub 2015. PMID: 26032863.
18. Zhou C, Urbauer DL, Fellman BM, Tamboli P, Zhang M, Matin SF, Wood CG, Karam JA. Metastases to the Kidney: A Comprehensive Analysis of 151 Patients from a Tertiary Referral Center. BJU Int 117(5):775-82, 2016. e-Pub 2015. PMID: 26053895.
19. Zhou L, Liu XD, Sun M, Zhang X, German P, Bai S, Ding Z, Tannir N, Wood CG, Matin SF, Karam JA, Tamboli P, Sircar K, Rao P, Rankin EB, Laird DA, Hoang AG, Walker CL, Giaccia AJ, Jonasch E. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 35(21):2687-97, 2016. e-Pub 2015. PMID: 26364599.
20. Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK. Everolimus versus Sunitinib Prospective Evaluation in Metastatic Non-clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol 69(5):866-74, 2016. e-Pub 2015. PMID: 26626617.
21. Borregales LD, Kim DY, Staller AL, Qiao W, Thomas AZ, Adibi M, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Prognosticators and Outcomes of Patients with Renal Cell Carcinoma and Adjacent Organ Invasion Treated with Radical Nephrectomy. Urol Oncol 34(5):237.e19-26, 2016. e-Pub 2015. PMID: 26707613.
22. Karam JA, Devine CE, Fellman BM, Urbauer DL, Abel EJ, Allaf ME, Bex A, Lane BR, Thompson RH, Wood CG. Variability of Inter-observer Agreement on Feasibility of Partial Nephrectomy Before and After Neoadjuvant Axitinib for Locally Advanced RCC: Independent Analysis from a Phase II Trial. BJU Int 117(4):629-35, 2016. e-Pub 2015. PMID: 26033220.
23. Lotan Y, Karam JA, Shariat SF, Gupta A, Roupret M, Bensalah K, Margulis V. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. Urol Oncol 34(4):167.e9-167.e16, 2016. e-Pub 2015. PMID: 26602092.
24. Mendoza-Pérez J, Gu J, Herrera LA, Tannir NM, Matin SF, Karam JA, Huang M, Chang DW, Wood CG, Wu X. Genomic DNA hypomethylation and risk of renal cell carcinoma: A case-control study. Clin Cancer Res 22(8):2074-82, 2016. e-Pub 2015. PMID: 26655847.
25. Thomas AZ, Adibi M, Slack RS, Borregales LD, Merrill MM, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. The Role Of Metastasectomy In Patients With Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol. e-Pub 2016. PMID: 27036304.
26. Adibi M, Kenney PA, Thomas AZ, Borregales LD, Nogueras-González GM, Wang X, Devine CE, Karam JA, Wood CG. Prediction of Pulmonary Metastasis in Renal Cell Carcinoma Patients with Indeterminate Pulmonary Nodules. Eur Urol 69(2):352-60, 2016. e-Pub 2015. PMID: 26382085.
27. Melquist JJ, Redrow G, Delacroix S, Park A, Faria EE, Karam JA, Matin SF. Comparison of Single-Docking Robotic-Assisted and Traditional Laparoscopy for Retroperitoneal Lymph Node Dissection during Nephroureterectomy with Bladder Cuff Excision for Upper-Tract Urothelial Carcinoma. Urology 87:216-23, 2016. e-Pub 2015. PMID: 26494291.
28. Melkonian SC, Daniel CR, Ye Y, Tannir NM, Karam JA, Matin SF, Wood CG, Wu X. Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell carcinoma. Cancer 122(1):108-15, 2016. e-Pub 2015. PMID: 26551148.
29. Mbeutcha A, Lucca I, Margulis V, Karam JA, Wood CG, de Martino M, Mathieu R, Haitel A, Xylinas E, Kluth L, Rouprêt M, Karakiewicz PI, Briganti A, Rink M, Rieken M, Weizer AZ, Raman JD, Rioux-Leclecq N, Bolenz C, Bensalah K, Lotan Y, Seitz C, Remzi M, Shariat SF, Klatte T. Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World J Urol. e-Pub 2015. PMID: 26658888.
30. Mathieu R, Klatte T, Margulis V, Karam JA, Rouprêt M, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Rink M, Kluth LA, Scherr DS, Robinson BD, Shariat SF. Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol 33(11):495.e15-22, 2015. e-Pub 2015. PMID: 26228160.
31. Adibi M, Thomas AZ, Borregales LD, Merrill MM, Slack RS, Chen HC, Sircar K, Murugan P, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol 33(10):427.e17-23, 2015. e-Pub 2015. PMID: 26004164.
32. Sircar K, Yoo SY, Majewski T, Wani K, Patel LR, Voicu H, Torres-Garcia W, Verhaak RG, Tannir N, Karam JA, Jonasch E, Wood CG, Tamboli P, Baggerly KA, Aldape KD, Czerniak B. Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. J Pathol Clin Res 1(4):212-24, 2015. e-Pub 2015. PMID: 27499906.
33. Lee BM, Singh Ghotra V, Karam JA, Hernandez M, Pratt G, Cata JP. Regional anesthesia/analgesia and the risk of cancer recurrence and mortality after prostatectomy: A meta-analysis. Pain Manag 5(5):1-9, 2015. e-Pub 2015. PMID: 26250850.
34. Singh RR, Murugan P, Patel LR, Voicu H, Yoo SY, Majewski T, Mehrotra M, Wani K, Tannir N, Karam JA, Jonasch E, Wood CG, Creighton CJ, Medeiros LJ, Broaddus RR, Tamboli P, Baggerly KA, Aldape KD, Czerniak B, Luthra R, Sircar K. Intratumoral Morphologic and Molecular Heterogeneity of Rhabdoid Renal Cell Carcinoma: Challenges for Personalized Therapy. Mod Pathol 28(9):1225-35, 2015. e-Pub 2015. PMID: 26111976.
35. Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E. Resistance to anti-angiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol Res 3(9):1017-29, 2015. e-Pub 2015. PMID: 26014097.
36. Thomas AZ, Adibi M, Borregales LD, Hoang LN, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Surgical Management for Local Retroperitoneal Recurrence Of Renal Cell Carcinoma After Radical Nephrectomy. J Urol 194(2):316-22, 2015. e-Pub 2015. PMID: 25758610.
37. Kenney PA, Vikram R, Prasad SR, Tamboli P, Matin SF, Wood CG, Karam JA. Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney: A Retrospective Detailed Study of Radiologic, Pathologic and Clinical Outcomes. BJU Int 116(1):85-92, 2015. e-Pub 2015. PMID: 25395040.
38. Pal SK, Choueiri TK, Wang K, Khaira D, Karam JA, Van Allen E, Palma NA, Stein MN, Johnson A, Squillace R, Elvin JA, Chmielecki J, Yelensky R, Yakirevich E, Lipson D, Lin DI, Miller VA, Stephens PJ, Ali SM, Ross JS. Characterization of clinical cases of collecting duct carcinoma of the kidney assessed by comprehensive genomic profiling. Eur Urol. e-Pub 2015. PMID: 26149668.
39. Krabbe LM, Bagrodia A, Haddad AQ, Kapur P, Khalil D, Hynan LS, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Margulis V. Multi-Institutional Validation of the Predictive Value of KI-67 in Patients with High-Grade Urothelial Carcinoma of the Upper Urinary Tract. J Urol 193(5):1486-93, 2015. e-Pub 2014. PMID: 25451830.
40. Babaian KN, Kim DY, Kenney PA, Wood CG, Wong J, Sanchez C, Fang JE, Gerber JA, Didic A, Wahab A, Golla V, Torres C, Tamboli P, Qiao W, Matin SF, Wood CG, Karam JA. Preoperative Predictors of Pathologic Lymph Node Metastasis in Patients with Renal Cell Carcinoma Undergoing RPLND. J Urol 193(4):1101-7, 2015. e-Pub 2014. PMID: 25390078.
41. Merrill MM, Wood CG, Tannir NM, Slack RS, Babaian KN, Jonasch E, Pagliaro LC, Compton Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA. Clinically Non-Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: Natural History and Outcomes after Surgical Resection with Curative Intent. Urol Oncol 33(4):166.e21-9, 2015. e-Pub 2015. PMID: 25700975.
42. Gayed BA, Gillen J, Christie A, Peña-Llopis S, Xie XJ, Yan J,Karam JA, Raj G, Sagalowsky AI, Lotan Y, Margulis V, Brugarolas J. Prospective Evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with Renal Cell Carcinoma. BMC Urol 15(1):24. e-Pub 2015. PMID: 25885592.
43. Shah AY, Karam JA, Lim ZD, Ng CS, Tannir NM. Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?. Urol Case Rep 3(2):18-20, 2015. PMID: 26120560.
44. Karam JA, Wood CG, Compton ZR, Rao P, Vikram R, Ahrar K, Matin SF. Salvage Surgery After Energy Ablation For Renal Masses. BJU Int 115(1):74-80, 2015. e-Pub 2014. PMID: 24656119.
45. Pal SK, He M, Tong T, Wu H, Liu X, Lau C, Wang JH, Warden C, Wu X, Signoretti S, Choueiri TK, Karam JA, Jones JO. RNA-seq Reveals Aurora Kinase Driven-mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. Mol Cancer Res 13(1):130-7, 2015. e-Pub 2014. PMID: 25183163.
46. Koh MY, Nguyen V, Lemos R, Darnay BG, Kiriakova G, Abdelmelek M, Ho TH, Karam J, Monzon FA, Jonasch E, Powis G. Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF-2 in clear cell renal cell carcinoma. Cancer Res 75(2):316-29, 2015. e-Pub 2014. PMID: 25421578.
47. Karmali RJ, Suami H, Wood CG, Karam JA. Lymphatic Drainage In Renal Cell Carcinoma: Back To The Basics. BJU Int 114(6):806-17, 2014. e-Pub 2014. PMID: 24841690.
48. Abel EJ, Carrasco A, Karam JA, Tamboli P, Delacroix S, Vaporciyan AA, Wood CG. Positive vascular wall margins have minimal impact on cancer outcomes in non-metastatic RCC patients with tumor thrombus. BJU Int 114(5):667-73, 2014. e-Pub 2014. PMID: 24128265.
49. Karam JA, Devine CE, Urbauer DL, Lozano M, Maity T, Ahrar K, Tamboli P, Tannir NM, Wood CG. Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma. Eur Urol 66(5):874-80, 2014. e-Pub 2014. PMID: 24560330.
50. Lee DJ, Xylinas E, Rieken M, Khani F, Klatte T, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Guo CC, Rioux-Leclercq N, Haitel A, Bolenz C, Bensalah K, Sagalowsky AI, Montorsi F, Lotan Y, Shariat SF, Robinson BD, Margulis V. Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. Eur Urol 66(2):379-85, 2014. e-Pub 2013. PMID: 24388440.
51. Babaian KN, Merrill MM, Matin S, Tamboli P, Tannir NM, Jonasch E, Wood CG, Karam JA. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol 192(1):36-42, 2014. e-Pub 2014. PMID: 24518767.
52. Culp SH, Karam JA, Wood CG. Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era. Urol Oncol 32(5):561-8, 2014. e-Pub 2014. PMID: 24709415.
53. Faria EF, Caputo PA, Wood CG, Karam JA, Nogueras-González GM, Matin SF. Robotic partial nephrectomy shortens warm ischemia time, reducing suturing time kinetics even for an experienced laparoscopic surgeon: a comparative analysis. World J Urol 32(1):265-71, 2014. e-Pub 2013. PMID: 23783881.
54. Parker PA, Alba F, Fellman B, Urbauer DL, Li Y, Karam JA, Tannir N, Jonasch E, Wood CG, Matin SF. Illness Uncertainty and Quality of Life of Patients with Small Renal Tumors Undergoing Watchful Waiting: A 2-year Prospective Study. Eur Urol 63(6):1122-7, 2013. e-Pub 2013. PMID: 23419322.
55. Karam JA, Ahrar K, Vikram R, Romero CA, Jonasch E, Tannir NM, Rao P, Wood CG, Matin SF. Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int 111(6):997-1005, 2013. e-Pub 2013. PMID: 23510233.
56. Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int 108(7):1119-23, 2011. e-Pub 2011. PMID: 21426474.
57. Abel EJ, Karam JA, Carrasco A, Matin SF. Laparoscopic adrenalectomy for metachronous metastases after ipsilateral nephrectomy for renal-cell carcinoma. J Endourol 25(8):1323-7, 2011. e-Pub 2011. PMID: 21774667.
58. Cost NG, Delacroix SE, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis V. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol 59(6):912-8, 2011. e-Pub 2011. PMID: 21367518.
59. Karam JA, Huang S, Fan J, Stanfield J, Schultz RA, Pong RC, Sun X, Mason RP, Xie XJ, Niu G, Chen X, Frenkel EP, Sagalowsky AI, Hsieh JT. Upregulation of TRAG3 gene in urothelial carcinoma of the bladder. Int J Cancer 128(12):2823-32, 2011. e-Pub 2010. PMID: 20734393.
60. Karam JA, Zhang XY, Tamboli P, Margulis V, Wang H, Abel EJ, Culp SH, Wood CG. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. Eur Urol 59(4):619-28, 2011. e-Pub 2010. PMID: 21167632.
61. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 185(2):439-44, 2011. e-Pub 2010. PMID: 21167518.
62. Karam JA, Ahrar K, Wood CG, Jonasch E, Vikram R, Romero C, Tannir N, Matin SF. Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol 184(5):1882-7, 2010. e-Pub 2010. PMID: 20846689.
63. Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, Nielsen ME, Müller SC, Sagalowsky AI, Lotan Y. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res 15(22):7012-9, 2009. e-Pub 2009. PMID: 19903782.
64. Karam JA, Raj GV. Growing teratoma syndrome. Urology 74(4):783-4, 2009. e-Pub 2009. PMID: 19647298.
65. Shariat SF, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Müller SC, Karam JA, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Cote RJ. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol 182(3):907-13, 2009. e-Pub 2009. PMID: 19616250.
66. Decker DB, Karam JA, Wilcox DT. Pediatric hemorrhagic cystitis. J Pediatr Urol 5(4):254-64, 2009. e-Pub 2009. PMID: 19303365.
67. Karam JA, Margulis V, Montorsi F, Karakiewicz PI, Lotan Y, Kikuchi E, Weizer A, Zigeuner R, Bolenz C, Shariat SF. Carcinoma in situ of the upper urinary tract treated with radical nephroureterectomy--results from a multicenter study. Eur Urol 54(4):961-3, 2008. e-Pub 2008. PMID: 18485573.
68. Shariat SF, Jenkins A, Roehrborn CG, Karam JA, Stage KH, Karakiewicz PI. Features and outcomes of patients with grade IV renal injury. BJU Int 102(6):728-33; discussion 733, 2008. e-Pub 2008. PMID: 18435808.
69. Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, Shariat SF. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clin Cancer Res 14(11):3362-6, 2008. PMID: 18519764.
70. Shariat SF, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V, Saad F, Slawin KM, Karakiewicz PI. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res 14(12):3785-91, 2008. PMID: 18559597.
71. Karam JA, Kabbani W, Sagalowsky AI. Pseudosarcomatous fibromyxoid tumor of the bladder. Urol Oncol 26(3):291-4, 2008. e-Pub 2007. PMID: 18452822.
72. Karam JA, Svatek RS, Karakiewicz PI, Gallina A, Roehrborn CG, Slawin KM, Shariat SF. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. Clin Cancer Res 14(5):1418-22, 2008. PMID: 18316564.
73. Svatek RS, Karam JA, Karakiewicz PI, Gallina A, Casella R, Roehrborn CG, Shariat SF. Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma. J Urol 179(2):478-84; discussion 484, 2008. PMID: 18076936.
74. Fan J, Stanfield J, Guo Y, Karam JA, Frenkel E, Sun X, Hsieh JT. Effect of trans-2,3-dimethoxycinnamoyl azide on enhancing antitumor activity of romidepsin on human bladder cancer. Clin Cancer Res 14(4):1200-7, 2008. PMID: 18281555.
75. Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology 70(3):482-6, 2007. PMID: 17905101.
76. Shariat SF, Bensalah K, Karam JA, Roehrborn CG, Gallina A, Lotan Y, Slawin KM, Karakiewicz PI. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. Clin Cancer Res 13(18 Pt 1):5377-84, 2007. PMID: 17875766.
77. Karam JA, Vazquez DV, Lin VK, Zimmern PE. Elastin expression and elastic fibre width in the anterior vaginal wall of postmenopausal women with and without prolapse. BJU Int 100(2):346-50, 2007. e-Pub 2007. PMID: 17532852.
78. Karam JA, Shariat SF, Huang HY, Pong RC, Ashfaq R, Shapiro E, Lotan Y, Sagalowsky AI, Wu XR, Hsieh JT. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin Cancer Res 13(15 Pt 1):4400-6, 2007. PMID: 17671122.
79. Karam JA, Baker LA. Focal orchitis presenting as bilateral testicular masses. J Pediatr Urol 3(4):337-9, 2007. e-Pub 2006. PMID: 18947769.
80. Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 67(6):614-22, 2007. PMID: 17299799.
81. Karam JA, Fan J, Stanfield J, Richer E, Benaim EA, Frenkel E, Antich P, Sagalowsky AI, Mason RP, Hsieh JT. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int J Cancer 120(8):1795-802, 2007. PMID: 17230511.
82. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Shariat SF. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 8(2):128-36, 2007. PMID: 17267327.
83. Svatek RS, Karam JA, Rogers TE, Schulman, MS, Margulis V, Benaim EA.. Intraluminal crystalloids are highly associated with prostatic adenocarcinoma on concurrent biopsy specimens. Prostate Cancer & Prostatic Dis 10(3):279-282, 2007. PMID: 17325718.
84. Svatek R, Karakiewicz PI, Shulman M, Karam JA, Perrotte P, Benaim E. Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer. Eur Urol 49(4):666-74, 2006. e-Pub 2006. PMID: 16423446.
85. Chen H, Karam JA, Schultz R, Zhang Z, Duncan C, Hsieh JT. Cloning of mouse Dab2ip gene, a novel member of the RasGTPase-activating protein family and characterization of its regulatory region in prostate. DNA Cell Biol 25(4):232-45, 2006. PMID: 16629596.
86. Zhang Z, Karam JA, Frenkel E, Sagalowsky A, Hsieh JT. The application of epigenetic modifiers on the treatment of prostate and bladder cancer. Urol Oncol 24(2):152-60, 2006. PMID: 16520279.
87. Shariat SF, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol 48(3):424-31, 2005. PMID: 15963628.
88. Nasr R, El-Sabban ME, Karam JA, Dbaibo G, Kfoury Y, Arnulf B, Lepelletier Y, Bex F, de The H, Hermine O, Bazarbachi A.. Efficacy and Mechanism of Action of the Proteasom Inhibitor PS-341 in T-Cell Lymphomas and HTLV-I Associated Adult T-Cell Leukemia/Lymphoma. Oncogene 13(24):419-430, 2005. PMID: 15543232.
89. Benaim EA, Karam JA, Soboorian MH, Roehrborn CG, McConnell JD, Lin V. The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate. Prostate 60(4):310-6, 2004. PMID: 15264242.
90. Shulman MJ, Karam JA, Benaim EA. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. Urology 63(4):732-6, 2004. PMID: 15072890.
91. Karam JA, Baker LA. Images in clinical medicine. True hermaphroditism. N Engl J Med 350(4):393, 2004. PMID: 14736931.

Invited Articles

1. Borregales LD, Adibi M, Thomas AZ, Wood CG, Karam JA. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol 8(2):130-41, 2016. e-Pub 2015. PMID: 27034725.
2. Thomas AZ, Blute ML, Seitz C, Habra MA, Karam JA. Management of The Incidental Adrenal Mass. Eur Urol Focus 1(3):223-230, 2016.
3. Adibi M, Thomas AZ, Borregales LD, Matin SF, Wood CG, Karam JA. Surgical Considerations for Patients with Metastatic Renal Cell Carcinoma. Urol Oncol 33(12):528-37, 2015. e-Pub 2015. PMID: 26546481.
4. Pal SK, Choueiri TK, Karam JA, Heng DY. Metastatic renal cell carcinoma: Contending with a sea change in therapy. Urol Oncol 33(12):507-8, 2015. PMID: 26584741.
5. Karam JA, Babaian KN, Tannir NM, Matin SF, Wood CG. Role of partial nephrectomy as cytoreduction in the management of metastatic renal cell carcinoma. Minerva Urol Nefrol 67(2):149-56, 2015. e-Pub 2015. PMID: 25645343.
6. Thomas AZ, Adibi M, Borregales LD, Wood CG, Karam JA. Role of Metastasectomy in Metastatic Renal Cell Carcinoma. Curr Opin Urol. e-Pub 2015. PMID: 26125508.
7. Thomas AZ, Adibi M, Borregales LD, Karam JA, Wood CG. Cytoreductive surgery in the era of targeted molecular therapy. Transl Androl Urol 4(3):301-309, 2015. PMID: 26815334.
8. Kim DY, Karam JA, Wood CG. Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. World J Urol 32(3):631-42, 2014. e-Pub 2014. PMID: 24744223.
9. Ngo TC, Wood CG, Karam JA. Biomarkers of renal cell carcinoma. Urol Oncol 32(3):243-51, 2014. e-Pub 2013. PMID: 24239464.
10. Karam JA. Cautious Approach Advised Until Compelling Evidence for Cytoreductive Nephrectomy Emerges from Pivotal Trials. Kidney Cancer Journal 12(1):27-29, 2014.
11. Sudarshan S, Karam JA, Brugarolas J, Thompson RH, Uzzo R, Rini B, Margulis V, Patard JJ, Escudier B, Linehan WM. Metabolism of Kidney Cancer: From the Lab to Clinical Practice. Eur Urol 63(2):244-51, 2013. e-Pub 2012. PMID: 23063455.
12. Wood CG, Karam JA. Co-Clinical trials, using personalized tumor xenograft models, usher in a new paradigm to understand biology of RCC and response to treatment. Kidney Cancer Journal 10(3):70-76, 2012.
13. Karam JA, Wood CG. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy. Hematol Oncol Clin North Am 25(4):753-64, 2011. PMID: 21763966.
14. Karam JA, Ahrar K, Matin SF. Ablation of kidney tumors. Surg Oncol Clin N Am 20(2):341-53, viii, 2011. e-Pub 2010. PMID: 21377587.
15. Karam JA, Kamat AM. Optimal timing of chemotherapy and cystectomy. F1000 Med Rep 2, 2010. e-Pub 2010. PMID: 20948836.
16. Karam JA, Wood CG. Management of Kidney Cancer with Tumor Thrombus. TTMed Urology, 2010.
17. Karam JA, Shariat SF, Hsieh JT, Knowles MA. Genomics: a preview of genomic medicine. BJU Int 102(9 Pt B):1221-7, 2008. PMID: 19035885.
18. Shariat SF, Karam JA, Raman JD. Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. Biomark Med 2(2):165-80, 2008. PMID: 20477438.
19. Shariat SF, Karam JA, Margulis V, Karakiewicz PI. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU Int 101(6):675-83, 2008. e-Pub 2007. PMID: 17941930.
20. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol 18(1):1-8, 2008. PMID: 18090481.
21. Shariat SF, Karam JA, Lotan Y, Karakiewizc PI. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 10(2):120-35, 2008. PMID: 18660854.
22. Bensalah K, Lotan Y, Karam JA, Shariat SF.. New circulating biomarkers for prostate cancer. Prostate Cancer & Prostatic Dis 11(2):112-120, 2008. PMID: 17998918.
23. Shariat SF, Karam JA, Roehrborn CG. Blood biomarkers for prostate cancer detection and prognosis. Future Oncol 3(4):449-61, 2007. PMID: 17661720.
24. Karam JA, Lotan Y, Shariat SF.. Urine Cytology and Commercially Available Urine-Based Markers for Monitoring of Bladder Urothelial Carcinoma. Lab Medicine 38(1):48-52, 2007.
25. Karam JA, Lotan Y, Shariat SF.. Bladder Cancer Screening and Future Directions in Urine-Based Markers for Bladder Urothelial Carcinoma. Lab Medicine 38(2):116-120, 2007.
26. Karam JA, Mason RP, Koeneman KS, Antich PP, Benaim EA, Hsieh JT. Molecular imaging in prostate cancer. J Cell Biochem 90(3):473-83, 2003. PMID: 14523981.

Editorials

1. Adibi M, Karam JA, Wood CG. Reporting Geographic and Temporal Trends in Renal Cell Carcinoma: Why Is This Important?. Eur Urol 67(3):531-2, 2015. PMID: 25454608.
2. Kim DY, Karam JA. For the RECORD, We Should SWITCH Our Treatment AXIS Before the SUNRISES and TARGET the BEST Treatments Before INTORSECTing with a GOLD METEOR: A Tale of Sequences and Combinations. Eur Urol 67(1):111-3, 2015. PMID: 24953406.
3. Kim DY, Karam JA. Editorial Comment to Growing teratoma syndrome: Clinical and radiographic characteristics. Int J Urol 21(9):909, 2014. PMID: 24796961.
4. Karam JA, Wood CG. Re: Prognostic or Predictive Plasma Cytokines and Angiogenic Factors for Patients Treated with Pazopanib for Metastatic Renal-cell Cancer: A Retrospective Analysis of Phase 2 and Phase 3 Trials. Eur Urol 63(4):769, 2013. PMID: 23438394.
5. Karam JA, Wood CG. Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Agents: A Review. Urology 81(1):208, 2013.
6. Kenney PA, Karam JA. PERCUTANEOUS CRYOABLATION OF SOLITARY SPORADIC RENAL CELL CARCINOMAS. BJU Int 110(11 Pt B):E532, 2012. PMID: 22583351.
7. Kenney PA, Karam JA. HIGHER PERIOPERATIVE MORBIDITY AND IN-HOSPITAL MORTALITY IN PATIENTS WITH END-STAGE RENAL DISEASE UNDERGOING NEPHRECTOMY FOR NON-METASTATIC KIDNEY CANCER: A POPULATION-BASED ANALYSIS. BJU Int 110(6 Pt B):E191, 2012. PMID: 22321381.
8. Karam JA, Wood CG.. The Effects of Temporary Ischemia in Partial Nephrectomy on Renal Functional Outcomes: How Can Effects Best Be Estimated, and Can They Be Mitigated?. Eur Urol 62(1):136-8, 2012. PMID: 22410575.
9. Karam JA, Wood CG. Management of Small Renal Masses: Watch, Cut, Freeze, or Fry?. Eur Urol 61(5):905-6, 2012. PMID: 22310973.
10. Kenney PA, Karam JA. Editorial Comment. J Urol 187(2):492, 2012. PMID: 22177914.
11. Karam JA. Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2. BJU Int 108(4):537-8, 2011. PMID: 21371243.
12. Karam JA, Wood CG. The dark side of targeted therapy. Eur Urol 59(4):541-2, 2011. PMID: 21295398.
13. Karam JA, Wood CG. Editorial comment. J Urol 183(3):870; discussion 870, 2010. PMID: 20083268.
14. Shariat SF, Karam JA, Karakiewicz PI. Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. N Engl J Med 2007;356:2271-81. Eur Urol 55(1):250-2, 2009. PMID: 20050019.
15. Karam JA, Sagalowsky AI. Minimally invasive radical cystectomy for bladder cancer?. Lancet Oncol 9(4):317-8, 2008. PMID: 18374289.
16. Hsieh JT, Karam JA, Min W. Genetic and biologic evidence that implicates a gene in aggressive prostate cancer. J Natl Cancer Inst 99(24):1823-4, 2007. PMID: 18073373.

Book Chapters

1. Merrill MM, Karam JA. Renal Cancer: Contemporary Management. In: Post-Operative Surveillance Protocols, 2012.
2. Karam JA, Wood CG. Surgical Management of Metastatic/Advanced Kidney Cancer. In: Comprehensive Textbook of Genitourinary Oncology. 4th. Lippincott Williams & Wilkins, 973, 2011.
3. Karam JA, Wood CG. Genitourinary Cancer. In: M. D. Anderson Surgical Oncology Handbook. 5th. Lippincott Williams & Wilkins, 920, 2011.
4. Karam, JA, Hsieh JT. Anti-Cancer strategy of transitional cell carcinoma of bladder based on induction of different types of programmed cell deats. In: Apoptosis in Carcinogenesis and Chemotherapy. Springer, 25-50, 2009.
5. Karam JA, Benaim EA, Chen H, Pong RC, Hsieh JT. Epigenetics in prostate cancer. In: Prostate Cancer: Basic mechanisms and therapeutic approaches. World Scientific Publishing Co: New Jersey, 213-228, 2005.